Cancer-associated mutations in the spliceosome gene SF3B1 create a neomorphic protein that produces aberrant mRNA splicing in hundreds of genes, but the ensuing biologic and therapeutic consequences of this missplicing are not well understood. Here we have provided evidence that aberrant splicing by mutant SF3B1 altered the transcriptome, proteome, and metabolome of human cells, leading to missplicing-associated downregulation of metabolic genes, decreased mitochondrial respiration, and suppression of the serine synthesis pathway. We also found that mutant SF3B1 induces vulnerability to deprivation of the nonessential amino acid serine, which was mediated by missplicing-associated downregulation of the serine synthesis pathway enzyme PHGDH. This vulnerability was manifest both in vitro and in vivo, as dietary restriction of serine and glycine in mice was able to inhibit the growth of SF3B1MUT xenografts. These findings describe a role for SF3B1 mutations in altered energy metabolism, and they offer a new therapeutic strategy against SF3B1MUT cancers.
W. Brian Dalton, Eric Helmenstine, Noel Walsh, Lukasz P. Gondek, Dhanashree S. Kelkar, Abigail Read, Rachael Natrajan, Eric S. Christenson, Barbara Roman, Samarjit Das, Liang Zhao, Robert D. Leone, Daniel Shinn, Taylor Groginski, Anil K. Madugundu, Arun Patil, Daniel J. Zabransky, Arielle Medford, Justin Lee, Alex J. Cole, Marc Rosen, Maya Thakar, Alexander Ambinder, Joshua Donaldson, Amy E. DeZern, Karen Cravero, David Chu, Rafael Madero-Marroquin, Akhilesh Pandey, Paula J. Hurley, Josh Lauring, Ben Ho Park
Title and authors | Publication | Year |
---|---|---|
Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape
Cook AL, Sur S, Dobbyn L, Watson E, Cohen JD, Ptak B, Lee BS, Paul S, Hsiue E, Popoli M, Vogelstein B, Papadopoulos N, Bettegowda C, Gabrielson K, Zhou S, Kinzler KW, Wyhs N |
eLife | 2025 |
Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML
Sinanidis I, Tsakiroglou P, Dubner B, Foertsch R, Gondek J, Choi I, Paun B, Zhao L, Ghiaur G, Dalton WB |
bioRxiv | 2025 |
SF3B1 mutations provide genetic vulnerability to copper ionophores in human acute myeloid leukemia
Moison C, Gracias D, Schmitt J, Girard S, Spinella JF, Fortier S, Boivin I, Mendoza-Sanchez R, Thavonekham B, MacRae T, Mayotte N, Bonneil E, Wittman M, Carmichael J, Ruel R, Thibault P, Hébert J, Marinier A, Sauvageau G |
Science Advances | 2024 |
Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
Rombaut D, Lefèvre C, Rached T, Bondu S, Letessier A, Mangione RM, Farhat B, Lesieur-Pasquier A, Castillo-Guzman D, Boussaid I, Friedrich C, Tourville A, De Carvalho M, Levavasseur F, Leduc M, Le Gall M, Battault S, Temple M, Houy A, Bouscary D, Willems L, Park S, Raynaud S, Cluzeau T, Clappier E, Fenaux P, Adès L, Margueron R, Wassef M, Alsafadi S, Chapuis N, Kosmider O, Solary E, Constantinou A, Stern MH, Droin N, Palancade B, Miotto B, Chédin F, Fontenay M |
Nature Communications | 2024 |
Genomic dissection and mutation-specific target discovery for breast cancer PIK3CA hotspot mutations
Miranda AX, Kemp J, Davidson BA, Bellomo SE, Miranda VE, Manoni A, Marchiò C, Croessmann S, Park BH, Hodges E |
BMC Genomics | 2024 |
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
Choi IY, Ling JP, Zhang J, Helmenstine E, Walter W, Tsakiroglou P, Bergman RE, Philippe C, Manley JL, Rouault-Pierre K, Li B, Wiseman DH, Batta K, Ouseph M, Bernard E, Dubner B, Li X, Haferlach T, Koget A, Fazal S, Jain T, Gocke CD, DeZern AE, Dalton WB |
Blood advances | 2024 |
ASCT2 is a major contributor to serine uptake in cancer cells.
Conger KO, Chidley C, Ozgurses ME, Zhao H, Kim Y, Semina SE, Burns P, Rawat V, Lietuvninkas L, Sheldon R, Ben-Sahra I, Frasor J, Sorger PK, DeNicola GM, Coloff JL |
Cell reports | 2024 |
Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Fernandez MM, Yu L, Jia Q, Wang X, Hart KL, Jia Z, Lin RJ, Wang L |
Cancer Research Communications | 2024 |
Implications for Metabolic Disturbances in Myelodysplastic Syndromes
McGraw KL, Larson DR |
Seminars in hematology | 2024 |
Genome sequencing in the management of myelodysplastic syndromes and related disorders
Cazzola M, Malcovati L |
Haematologica | 2024 |
Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
Zavras PD, Sinanidis I, Tsakiroglou P, Karantanos T |
International journal of molecular sciences | 2023 |
A multimodal analysis of genomic and RNA splicing features in myeloid malignancies
Durmaz A, Gurnari C, Hershberger CE, Pagliuca S, Daniels N, Awada H, Awada H, Adema V, Mori M, Ponvilawan B, Kubota Y, Kewan T, Bahaj WS, Barnard J, Scott J, Padgett RA, Haferlach T, Maciejewski JP, Visconte V |
iScience | 2023 |
The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.
Choi IY, Ling J, Zhang J, Helmenstine E, Walter W, Bergman R, Philippe C, Manley J, Rouault-Pierre K, Li B, Wiseman D, Ouseph M, Bernard E, Li X, Haferlach T, Fazal S, Jain T, Gocke C, DeZern A, Dalton WB |
Research square | 2023 |
Vitamin B5 and succinyl-CoA improve ineffective erythropoiesis in SF3B1-mutated myelodysplasia.
Mian SA, Philippe C, Maniati E, Protopapa P, Bergot T, Piganeau M, Nemkov T, Di Bella D, Morales V, Finch AJ, D'Alessandro A, Bianchi K, Wang J, Gallipoli P, Kordasti S, Kubasch AS, Cross M, Platzbecker U, Wiseman DH, Bonnet D, Bernard DG, Gribben JG, Rouault-Pierre K |
Science Translational Medicine | 2023 |
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland P, Saville H, Wai PT, Curnow L, Muirhead G, Nieminuszczy J, Ravindran N, John MB, Hedayat S, Barker HE, Wright J, Yu L, Mavrommati I, Read A, Peck B, Allen M, Gazinska P, Pemberton HN, Gulati A, Nash S, Noor F, Guppy N, Roxanis I, Pratt G, Oldreive C, Stankovic T, Barlow S, Kalirai H, Coupland SE, Broderick R, Alsafadi S, Houy A, Stern MH, Pettit S, Choudhary JS, Haider S, Niedzwiedz W, Lord CJ, Natrajan R |
Nature Genetics | 2023 |
SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia.
López-Oreja I, Gohr A, Playa-Albinyana H, Giró A, Arenas F, Higashi M, Tripathi R, López-Guerra M, Irimia M, Aymerich M, Valcárcel J, Bonnal S, Colomer D |
Life science alliance | 2023 |
Prognostic value of amino acid metabolism-related gene expression in invasive breast carcinoma.
Wang Z, Guo X, Lian J, Ji Y, Li K |
Journal of Cancer Research and Clinical Oncology | 2023 |
Single-cell multi-omics defines the cell-type specific impact of splicing aberrations in human hematopoietic clonal outgrowths
Cortés-López M, Chamely P, Hawkins AG, Stanley RF, Swett AD, Ganesan S, Mouhieddine TH, Dai X, Kluegel L, Chen C, Batta K, Furer NS, Vedula RS, Beaulaurier J, Drong AW, Hickey S, Dusaj N, Mullokandov G, Stasiw AM, Su J, Chaligné R, Juul S, Harrington E, Knowles DA, Potenski CJ, Wiseman DH, Tanay A, Shlush L, Lindsley RC, Ghobrial IM, Taylor J, Abdel-Wahab O, Gaiti F, Landau DA |
Cell Stem Cell | 2023 |
ASCT2 is the primary serine transporter in cancer cells.
Conger KO, Chidley C, Ozgurses ME, Zhao H, Kim Y, Semina SE, Burns P, Rawat V, Sheldon R, Ben-Sahra I, Frasor J, Sorger PK, DeNicola GM, Coloff JL |
bioRxiv : the preprint server for biology | 2023 |
Expression of circular RNAs in myelodysplastic neoplasms and their association with mutations in the splicing factor gene SF3B1.
Trsova I, Hrustincova A, Krejcik Z, Kundrat D, Holoubek A, Staflova K, Janstova L, Vanikova S, Szikszai K, Klema J, Rysavy P, Belickova M, Kaisrlikova M, Vesela J, Cermak J, Jonasova A, Dostal J, Fric J, Musil J, Dostalova Merkerova M |
Molecular Oncology | 2023 |
Glycolysis Dependency as a Hallmark of SF3B1-Mutated Cells.
Vivet-Noguer R, Tarin M, Canbezdi C, Dayot S, Silva L, Houy A, Martineau S, Mieulet V, Gentric G, Loew D, Lombard B, Nemati F, Richon S, Guyonnet L, Servois V, Vagner S, Stern MH, Roman-Roman S, Alsafadi S |
Cancers | 2022 |
Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis
Krasny L, Wilding CP, Perkins E, Arthur A, Guljar N, Jenks AD, Fisher C, Judson I, Thway K, Jones RL, Huang PH |
Cancers | 2022 |
Cell-specific regulation of gene expression using splicing-dependent frameshifting
Ling JP, Bygrave AM, Santiago CP, Carmen-Orozco RP, Trinh VT, Yu M, Li Y, Liu Y, Bowden KD, Duncan LH, Han J, Taneja K, Dongmo R, Babola TA, Parker P, Jiang L, Leavey PJ, Smith JJ, Vistein R, Gimmen MY, Dubner B, Helmenstine E, Teodorescu P, Karantanos T, Ghiaur G, Kanold PO, Bergles D, Langmead B, Sun S, Nielsen KJ, Peachey N, Singh MS, Dalton WB, Rajaii F, Huganir RL, Blackshaw S |
Nature Communications | 2022 |
SF3B1 Mutations in Hematological Malignancies
Cilloni D, Itri F, Bonuomo V, Petiti J |
Cancers | 2022 |
Mutant SF3B1 promotes AKT and NF-kB driven mammary tumorigenesis
Bo Liu, Zhaoqi Liu, Sisi Chen, Michelle Ki, Caroline Erickson, Jorge S. Reis-Filho, Benjamin H. Durham, Qing Chang, Elisa de Stanchina, Yiwei Sun, Raul Rabadan, Omar Abdel-Wahab, Sarat Chandarlapaty |
Journal of Clinical Investigation | 2021 |
Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones
Swathi Karthikeyan, Ian G. Waters, Lauren Dennison, David Chu, Joshua Donaldson, Dong Ho Shin, D Marc Rosen, Paula I Gonzalez-Ericsson, Violeta Sanchez, Melinda Sanders, Morgan V Pantone, Riley E Bergman, Brad A. Davidson, Sarah C Reed, Daniel J. Zabransky, Karen Cravero, Kelly Kyker-Snowman, Berry Button, Hong Yuen Wong, Paula J Hurley, Sarah Croessmann, Ben Park |
Journal of Clinical Investigation | 2021 |
The Role of Metabolism in the Development of Personalized Therapies in Acute Myeloid Leukemia
V Dembitz, P Gallipoli |
Frontiers in Oncology | 2021 |
Targeting transcription cycles in cancer
SJ Vervoort, JR Devlin, N Kwiatkowski, M Teng, NS Gray, RW Johnstone |
Nature Reviews Cancer | 2021 |
Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer.
Noblejas-López MDM, López-Cade I, Fuentes-Antrás J, Fernández-Hinojal G, Esteban-Sánchez A, Manzano A, García-Sáenz JÁ, Pérez-Segura P, La Hoya M, Pandiella A, Győrffy B, García-Barberán V, Ocaña A |
Cancers | 2021 |
SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Yang JY, Huo YM, Yang MW, Shen Y, Liu DJ, Fu XL, Tao LY, He RZ, Zhang JF, Hua R, Jiang SH, Sun YW, Liu W |
Molecular Oncology | 2021 |
Molecular-Based Score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome.
Coelho-Silva JL, Silveira DRA, Pereira-Martins DA, Rojas CAO, Lucena-Araujo AR, Rego EM, Machado-Neto JA, Bendit I, Rocha V, Traina F |
Scientific Reports | 2021 |
The ins and outs of serine and glycine metabolism in cancer.
Geeraerts SL, Heylen E, De Keersmaecker K, Kampen KR |
Nature metabolism | 2021 |
Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms.
Hochman MJ, Savani BN, Jain T |
2021 | |
The PHGDH enigma: Do cancer cells only need serine or also a redox modulator?
AM Li, J Ye |
Cancer Letters | 2020 |
Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts
A Poulaki, T Katsila, IE Stergiou, S Giannouli, JC Gόmez-Tamayo, ET Piperaki, K Kambas, A Dimitrakopoulou, GP Patrinos, AG Tzioufas, M Voulgarelis |
Cancers | 2020 |
Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation
P Popli, MM Richters, SB Chadchan, TH Kim, E Tycksen, O Griffith, PH Thaker, M Griffith, R Kommagani |
Cell Death and Disease | 2020 |
ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase.
Williams RT, Guarecuco R, Gates LA, Barrows D, Passarelli MC, Carey B, Baudrier L, Jeewajee S, La K, Prizer B, Malik S, Garcia-Bermudez J, Zhu XG, Cantor J, Molina H, Carroll T, Roeder RG, Abdel-Wahab O, Allis CD, Birsoy K |
Cell Metabolism | 2020 |
The metabolic reprogramming and vulnerability of SF3B1 mutations.
Dalton WB |
Molecular & Cellular Oncology | 2020 |
The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing
Dalton WB, Helmenstine E, Pieterse L, Li B, Gocke CD, Donaldson J, Xiao Z, Gondek LP, Ghiaur G, Gojo I, Smith BD, Levis MJ, DeZern AE |
Blood Advances | 2020 |
CRISPR editing of sftb-1/SF3B1 in Caenorhabditis elegans allows the identification of synthetic interactions with cancer-related mutations and the chemical inhibition of splicing.
Serrat X, Kukhtar D, Cornes E, Esteve-Codina A, Benlloch H, Cecere G, Cerón J |
PLoS genetics | 2019 |